Abstract
Receptors associated with trace amines, 1st subtype (TAAR1), are the promising targets for the development of new pharmacological approaches to the treatment of various neuropsychiatric disorders. Currently TAAR1 agonists are undergoing clinical trials as new pharmacologically active agents with antipsychotic action. At the same time, the expression of TAAR1 and the physiological significance of these receptors as regulators of the activity of catecholaminergic structures in the Central nervous system suggest that the activation of TAAR1 can have a therapeutic effect in patients suffering from mental diseases such as obsessive-compulsive disorder and attention deficit hyperactivity disorder, which are accompanied by violations of impulsive and compulsive control. This paper is an attempt to critically evaluate the currently existing data set obtained during testing of TAAR1 ligands in in vivo studies over the past 5 years. The analysis suggests that TAAR1 agonists may provide and have a limited anti-compulsive effect when used in the clinic.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
